Naslov
Long term treatment of schizophrenic patients with olanzapine : A naturalistic study

Autori
Muck-Šeler, Dorotea ; Pivac, Nela ; Šagud, Marina ; Mihaljević-Peleš, Alma ; Mustapić, Maja ; Popović-Knapić, Vesna ; Jakovljević, Miro

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 4th Congress of the Federation of the European Pharmacological Societies (EPHAR) ; u: Fundamental and Clinical Pharmacology 18 (2004) (S1) ; Posters, 23–126 ; P 20.21 / Bousquet, Pascal ; Zannad, Faiez - Oxford : Wiley-Blackwell, 2004, 116-116

Skup
Congress of the Federation of the European Pharmacological Societies (4 ; 2004))

Mjesto i datum
Porto, Portugal, 17.07.2004. - 19.07.2004

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
olanzapine; schizophrenia; naturalistic study; positive and Negative Syndrome Scale; Clinical Global Impression scale

Sažetak
Olanzapine is a novel antipsychotic drug of the thienobenzodiazepine class. It is a potent antagonist of serotonergic 5-HT2A and dopaminergic D2 receptors with higher affinity for 5-HT2A than for D2 receptors. Aim. To determine the clinical response and safety of long term administration of olanzapine in schizophrenic patients. The study included 48 (30 male and 18 female) schizophrenic patients (mean age 33.9 ± 10 years, range 20-63 years). Patients were treated with olanzapine (mean dose 10.7 ± 5.0 mg/day, range 5-20mg/day) in a long term (23.0 ± 12.7 months, range 6-43 months) open study. Clinical diagnosis of schizophrenia was made according to the DSM-IV criteria. The efficacy measures included the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) scale. Standard laboratory tests for the determination of glucose levels, enzymes AST and ALT activity, number of white blood cells and QTc intervals in EKG were used. After long term (at least 6 months) treatment of schizophrenic patients with olanzapine a significant (p<0.001) improvement in all efficacy measures was observed. The mean weight gain was 8.1 kg ± 5.8 (range 1-26 kg). Side effects reported were somnolence (n=1), tremor (n=1) and fatigue (n=1). There was no significant difference from baseline in biochemical parameters (glucose, AST, ALT, white blood cells) and QTc intervals. Conclusions. Our results indicate that in our naturalistic study long term administration of olanzapine induced good therapeutic response with minor side effects, without significant alterations in biochemical parameters and EKG in schizophrenic patients.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

Napomena
DOI: 10.1111/j.1472-8206.2004.00260.x

POVEZANOST RADA